Kezar Life Sciences, Inc. (KZR) Misses Q3 EPS by 246c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($2.78), $2.46 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Polymarket and Yahoo Finance Partnership Expires
• BMO Capital Downgrades Magna Intl (MG:CN) (MGA) to Market Perform